Scientists hunt for clues to why some lymphomas shrug off powerful new drugs
NCT ID NCT07614035
First seen May 29, 2026 · Last updated Jun 16, 2026 · Updated 6 times
Summary
This study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are about to start treatment with bispecific antibodies. Researchers want to find out why some patients do not respond or have severe side effects. They will look at tumor samples, gut bacteria, and PET scans to identify patterns that predict success or failure. The goal is to help doctors choose the best treatment for each person in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Policlinico di Sant'Orsola
Bologna, Emilia-Romagna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.